http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I660951-B
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3cc98dfd7f88a3cfefcb5003434a767f |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-30 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate | 2015-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2019-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7f8d3528ecc6e8310a349278e600e3e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf13ff22a5a31470744b8526a557f19a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bc6826753a29ab1318d1223b47bbd88 |
publicationDate | 2019-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | TW-I660951-B |
titleOfInvention | Crystal form of acrolatine compound, drug containing the crystal form, and use thereof |
abstract | The present invention provides a crystalline form of an acridine compound, a medicine containing the crystalline form and uses thereof. The crystalline form is a solvent-free crystalline form. The X-ray powder diffraction obtained by Cu-Ka ray measurement at this form is 6.0 0 ± 0.2 0 , 11.4 0 ± 0.2 0 , 13.1 0 ± 0.2 0, and 18.9 0 ± 0.2 0 peaks. The invention also provides the use of the crystal form in the preparation of a medicament for resisting diseases related to abnormal cell proliferation. The crystal form of the present invention has high stability, does not have the risk of being transformed into other crystal forms, and is suitable for transportation and storage under extreme weather. |
priorityDate | 2014-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.